TrialsgrambetaRCTs are beautiful
ESC Congress 2026Presentado dom, 30 ago · 11:45 CESTHot Line 7Todos los ensayos Hot Line →

ACASA-TAVI

2026

AntiCoagulation versus AcetylSalicylic Acid after Transcatheter Aortic Valve Implantation

In 360 patients after TAVI without an indication for anticoagulation, 12 months of a factor Xa inhibitor reduced leaflet thrombosis on CT and a safety composite at 12 months compared with aspirin.

Resultado

Eficacia: co-primary: (1) incidence of hypo-attenuated leaflet thickening (HALT) on 4-dimensional cardiac CT at 12 months; (2) safety composite of VARC-3 bleeding, thromboembolic events (myocardial infarction, stroke) and all-cause death at 12 monthsrisk ratio 0,55 (IC del 95% 0,37-0,82) · P = 0,004

Por debajo de 1 a favor de 12 months of a factor Xa inhibitor, por encima de 1 a favor de aspirin.

Tasas de eventos
Diferencia absoluta
15,4 puntos
NNT
7

La diferencia absoluta y el NNT se derivan de las tasas de eventos.

También se informa: The safety composite of VARC-3 bleeding, thromboembolism and death ran 7.5% vs 10.6% (risk difference −3.3 percentage points, 95% CI −9.5 to 2.8; P < 0.001 for non-inferiority); bleeding was low overall and numerically higher on aspirin, with life-threatening or fatal bleeding only in that arm. Deaths 2 vs 10.

Publicación original
Subtema
TAVR antithrombotics
Diseño
investigator-sponsored, pragmatic, multicentre (Oslo and Bergen, Norway), prospective randomised open-label blinded-endpoint (PROBE) all-comers trial; 1:1 anti-factor Xa DOAC monotherapy vs aspirin; co-primary endpoints at 12 months; long-term follow-up to 5 and 10 years
Relevancia
Importante: uno de varios pilares.
Fuente
Dodgson S, Herstad J, Kløve SF, et al. JAMA. 2026; published online 30 August.doi 10.1001/jama.2026.17036

Discusión y crítica

A factor Xa inhibitor halves subclinical leaflet thrombosis after TAVI without paying for it in bleeding, in patients aged 65 to 80 with no other reason to anticoagulate. The endpoint is a CT finding, not an event, and GALILEO already showed that anticoagulating this population can cost lives, so the two deaths versus ten here are reassuring but far too few to answer that. What the trial establishes is the imaging effect and the absence of an obvious safety price at 360 patients; whether leaflet thickening is worth preventing remains the open question.